HAN-GINS Healthtech set to continue its strong growth trajectory as we come out of lockdown, says leading Manager of healthtech ETF
Anthony Ginsberg, Co-creator of HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL)
- Telemedicine patients expected to grow 3 fold from 2019 to 64 million in 2023
A spokesperson from the HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) says Healthcare Cloud spending has enabled Telemedicine to flourish during the Covid-19 crisis, and this will expand further as we return to normal because of its huge ‘convenience’ factor. Evidence of this includes the fact that many mainstream medical insurance plans now include insurance for Telemedicine.
In the US this is predicted to lead to a trebling in the number of telemedicine patients by 2023 to 64 million, from just 21 million in 2019. The annual growth rate in 2020 was almost 100%.
The WELL health ETF also expects Gene Sequencing and Robotics players (Intuitive Surgical) to enjoy significant growth as genomics become increasingly mainstream across the medical field: robotic surgery leads to less infections and reduced hospital stays. Healthcare Trackers/Wearables are increasingly popular too – the ETF expects Big Tech to become increasingly active in this space.
Anthony Ginsberg, Co-creator of HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL), said: “The Covid-19 crisis is forcing healthcare systems to innovate, fast-tracking digital health adoption rates. Cloud-based hospital spending is enjoying a boom and enabling new health-tech products and services. Gene Sequencing and Biotech areas are seen as increasingly mainstream for healthcare solutions such as vaccines.
“Remote Wearables/Trackers and Telemedicine are experiencing a huge surge due to private and government insurance now covering such procedures. Telemedicine is on track to grow by over 30% annualised between 2021-2025.
HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) has delivered a return of 35.48% over the past 12 months.
The WELL health ETF is a UCITS compliant Exchange Traded Fund domiciled in Ireland. It tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return), an index designed to measure the performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.